A Look at Novartis’s Innovative Medicines Business
Novartis’s (NVS) Innovative Medicines business, which includes prescription pharmaceutical and oncology products, contributed over 66% of Novartis’s total revenue in Q1 2018. Its revenue grew 12% YoY (year-over-year) to $8.4 billion.